Current Report Filing (8-k)
November 12 2021 - 07:30AM
Edgar (US Regulatory)
false 0001659323 0001659323 2021-11-12
2021-11-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 12,
2021
|
|
|
|
|
|
|
|
|
|
Iterum Therapeutics plc
|
|
|
(Exact name of registrant as specified in its charter)
|
|
|
Ireland
|
|
001-38503
|
|
98-1283148
|
|
(State or other jurisdiction
|
|
(Commission File Number)
|
|
(IRS Employer
|
|
of incorporation)
|
|
|
|
Identification No.)
|
|
|
|
|
|
|
|
|
|
Fitzwilliam Court, 1st Floor
Leeson Close
Dublin 2, D02 YW24
Ireland
|
|
Not Applicable
|
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
|
|
Registrant’s telephone number, including area code: +353 1 669 4820
|
|
|
|
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
☐
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of Each
Class
|
Trading Symbol
|
Name of Each Exchange on
Which Registered
|
|
Ordinary Shares, par value $0.01 per share
|
ITRM
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☒
Item 2.02. Results of Operations and Financial Condition.
On November 12, 2021, Iterum Therapeutics plc issued a press
release announcing its financial results for the third quarter
ended September 30, 2021. A copy of the press release is furnished
herewith as Exhibit 99.1.
The information in this current report on Form 8-K, including the
press release attached as Exhibit 99.1 hereto, is being furnished,
but shall not be deemed to be “filed” for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of that section or Sections 11 and
12(a)(2) of the Securities Act of 1933, as amended. The information
contained herein and in the accompanying exhibit shall not be
incorporated by reference into any filing with the U.S. Securities
and Exchange Commission made by Iterum Therapeutics, whether made
before or after the date hereof, regardless of any general
incorporation language in such filing.
Item 9.01. Financial Statements and
Exhibits.
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, as amended, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly
authorized.
|
|
|
Iterum Therapeutics plc
|
|
|
|
|
|
Dated: November 12, 2021
|
|
|
|
|
|
By:
|
/s/ Corey N. Fishman
|
|
|
|
|
|
Corey N. Fishman
|
|
|
|
|
Chief Executive Officer
|
Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart
From Jul 2022 to Aug 2022
Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart
From Aug 2021 to Aug 2022
